Published by Iain Gilbert on 7th May 2025
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its specifically engineered HER2-directed DXd antibody drug conjugate Enhertu.
URL: http://www.digitallook.com/dl/news/story/35061577/...